Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of childhood sexual and physical abuse on needs for care among people with first episode psychosis.

Child abuse & neglect·2025

Same author

Impact of GH Deficiency and Excess on Men Sexual Health and Fertility.

Frontiers of hormone research·2024

Same author

Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes.

Expert opinion on pharmacotherapy·2024

Same author

Pharmacological management of testosterone deficiency in men current advances and future directions.

Expert review of clinical pharmacology·2024

Same author

Effectiveness of the flash glucose monitoring system in preventing severe hypoglycemic episodes and in improving glucose metrics and quality of life in subjects with type 1 diabetes at high risk of acute diabetes complications.

Acta diabetologica·2024

Same author

Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis.

Expert opinion on drug safety·2024

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Selective serotonin reuptake inhibitor-induced sexual dysfunction.

Giovanni Corona¹, Valdo Ricca, Elisa Bandini

¹Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence 50139, Italy.

The Journal of Sexual Medicine

|May 29, 2009

Summary

Selective serotonin reuptake inhibitors (SSRIs) significantly increase the risk of male sexual dysfunction, including delayed ejaculation and erectile issues. Other antidepressants and benzodiazepines show fewer sexual side effects.

Related Experiment Videos

Last Updated: Jun 22, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Psychiatry and Endocrinology
Sexual Medicine

Background:

Mood disturbances often correlate with sexual dysfunctions.
Antidepressants, particularly SSRIs, can independently cause sexual side effects.

Purpose of the Study:

To investigate the link between SSRIs, non-SSRIs, benzodiazepines (BDZ), hormonal levels, and sexual dysfunction in men.
To assess sexual dysfunction using the Structured Interview on Erectile Dysfunction (SIEDY) and psychopathology with the Middlesex Hospital Questionnaire (MHQ).

Main Methods:

Studied 2,040 male patients (mean age 51) with sexual dysfunction.
Assessed hormonal and biochemical parameters, SIEDY, and MHQ.
Compared SSRI, non-SSRI antidepressant, and BDZ users.

Main Results:

SSRIs were linked to higher prolactin levels and a twofold increased risk of hypoactive sexual desire.
SSRIs showed a sevenfold increased risk for delayed ejaculation and impaired erectile function, but not penile blood flow.
Non-SSRI antidepressants were associated with mild delayed ejaculation, unlike SSRIs which affected all sexual response stages.

Conclusions:

SSRIs negatively impact male sexual response (desire, arousal, orgasm) and auto/couple-erotic function.
SSRI-associated sexual dysfunction is prevalent and affects multiple sexual parameters.
Benzodiazepines and non-SSRIs are less frequently associated with sexual impairment compared to SSRIs.